While tyrosine kinase inhibitors (TKIs) targeting mutant epidermal growth factor receptor (EGFR) have improved the survival of patients with non-small cell lung cancer (NSCLC) in the last decade, NSCLC patients with mutated EGFR are more likely to spread to the brain than those with wild-type EGFR [5–7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.